Vermillion Lowers Price Target on Public Offering | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion lowered the target of its follow-on offering of stock on Friday after the close of the market.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it will register 4.6 million shares of its common stock at $6.49 per share, raising a maximum of almost $29.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.